---
title: "on-demand webinar: Patient-derived organoids: an emerging platform to de-risk immunotherapy development"
description: Watch our on-demand webinar on the revolutionizing role of patient-derived organoids in de-risking immunotherapy development
image: https://resources.huborganoids.nl/hubfs/SocialMedia-Patient-Derived-Organoids-Webinar.jpg
---

[![Logo HUB Organoids](https://resources.huborganoids.nl/hubfs/raw_assets/public/HUBOrganoids_May2021/images/logo-huborganoids-white.svg "Logo HUB Organoids")](https://huborganoids.nl/)

![merk-m-logo-blue](https://resources.huborganoids.nl/hs-fs/hubfs/merk-m-logo-blue.png?width=728&height=225&name=merk-m-logo-blue.png)

On demand webinar

# Patient-derived organoids: an emerging platform to de-risk immunotherapy development

 Dr. Sylvia F. Boj, Chief Scientific Officer 

 

![](https://resources.huborganoids.nl/hs-fs/hubfs/assets2023/odw-patient-derived-organoids.jpg?width=400&name=odw-patient-derived-organoids.jpg)Recent advances in cancer immunotherapy had a positive impact on the life expectancy of patients with liquid cancers. With new treatment strategies and druggable targets being identified at an increasing pace, the number of patients eligible for cancer immunotherapy is expected to expand rapidly. However, promising therapeutic developments face hurdles in translating preclinical findings into therapy since conventional 2D cancer models hold low clinical predictive value. Patient-derived organoids (PDOs) generated from healthy and malignant tissues recapitulate complex characteristics of the original parental tissue, including molecular heterogeneity, and morphological and functional traits. Importantly they preserve tumor-specific antigens that are conventionally lost in standard in vitro models, therefore representing an excellent system to investigate target engagement, and mechanisms of action, and to stratify a patient population based on tumor molecular features. In this webinar, we will show how we have developed autologous PDO and immune cells biobanks relevant for testing immune-oncology agents and co-culture assays to evaluate different immuno-oncology products such as CAR-T cells, T cell engagers, and checkpoint inhibitors

#### Download our webinar to:

- Learn about the benefits of patient-derived organoids compared to standard *in vitro* models
- Find out about established co-culture systems and under-development projects
- Familiarize with how patient-derived organoids are currently being used to evaluate the efficacy of CAR-T cells, T cell engagers, and checkpoint inhibitors
- Understand patient-derived organoids applications across the drug development pipeline from target engagement/validation to the mechanism of action and lead selection studies
- Discover how organoids are helping to replace, refine, and reduce animal use in immunotherapy development

### Watch now

![Logo HUB Organoids](https://resources.huborganoids.nl/hubfs/raw_assets/public/HUBOrganoids_May2021/images/logo-huborganoids-white.svg "Logo HUB Organoids")

[Privacy Policy](https://huborganoids.nl/privacy-policy)

HUB Organoids is now part of the Life Science Business of Merck KGaA, Darmstadt, Germany

***FOR RESEARCH USE ONLY.**  Unless otherwise stated in our catalog or other company documentation  
 accompanying the product(s), our products are intended for research use only and are not to be used   
 for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro   
 diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to   
humans or animals.*